about
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemiaPreclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonistSTAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancerPreclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft modelsPharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trialsPharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutantsSHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met
P50
Q33873317-948F9558-470C-43B7-8895-3F8E66167ECBQ33873323-820A3A59-1BD7-469D-9648-2B142109113CQ49984769-19CCE60A-CAFB-47EB-AE8B-EF1ADE524338Q58692179-F02CB33D-FBA0-435D-8BBF-2A34C60CBE51Q58778783-1FC7CD38-4678-482E-8F54-734224C07700Q64099527-FB76D75D-7BB4-40C8-9449-53BC21BD1D37Q64236616-626632D0-4950-45F0-8DD6-72D945E9259CQ92284699-53650CD4-30D0-43A7-9FD1-DC5A608967A6Q92850878-8BB800C4-ED23-409E-A94B-8CAC07B17F24
P50
description
researcher
@en
wetenschapper
@nl
name
Liguang Lou
@en
Liguang Lou
@nl
type
label
Liguang Lou
@en
Liguang Lou
@nl
prefLabel
Liguang Lou
@en
Liguang Lou
@nl
P31
P496
0000-0001-7396-7122